• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

6.785 +0.115 (+1.72%)
Streaming Delayed Price Updated: 1:21 PM EDT, May 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 863,717
Open 6.600
Bid (Size) 6.780 (900)
Ask (Size) 6.790 (1,300)
Prev. Close 6.670
Today's Range 6.580 - 7.010
52wk Range 1.845 - 7.300
Shares Outstanding 64,465,037
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Taysha (TSHA) Q1 2026 Earnings Transcript ↗
May 07, 2026
Taysha (TSHA) Q1 2026 Earnings Transcript 
Via The Motley Fool
Taysha Gene Therapies (NASDAQ:TSHA) Reports Q1 2026 Miss, Reaffirms FDA Alignment on TSHA-102 Approval Path ↗
May 06, 2026
Via Chartmill

Performance

YTD
+29.2%
+29.2%
1 Month
+48.5%
+48.5%
3 Month
+53.9%
+53.9%
6 Month
+73.1%
+73.1%
1 Year
+257.1%
+257.1%

More News

Read More
News headline image
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 06, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
April 29, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
Taysha Gene Therapies Inc (NASDAQ:TSHA) Reports Q4 2025 Revenue Beat and Key Rett Syndrome Program Updates ↗
March 19, 2026
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
November 04, 2025
Via Benzinga
News headline image
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
April 27, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
April 02, 2026
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗
March 22, 2026
Via The Motley Fool
News headline image
Taysha (TSHA) Q4 2025 Earnings Call Transcript ↗
March 19, 2026
Via The Motley Fool
Topics Earnings
News headline image
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
March 19, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
March 12, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Inc (NASDAQ:TSHA) Stock Slumps on Q3 Revenue Miss Despite Key Regulatory Win for TSHA-102 ↗
November 04, 2025
Via Chartmill
News headline image
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
October 20, 2025
Via Benzinga
News headline image
Why Is Taysha Gene Therapies Stock Falling Friday? ↗
October 17, 2025
Via Benzinga
News headline image
Taysha Gene Therapies Stock Soars To 3-Year High After FDA Boost — Wall Street Calls Rett Drug ‘Derisked’ And Ahead Of Rivals ↗
October 03, 2025
Via Stocktwits
News headline image
Healthcare Sector Shines Amidst Market Turbulence, Bolstering S&P 500 Resilience
October 02, 2025
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Demystifying Taysha Gene Therapies: Insights From 6 Analyst Reviews ↗
October 02, 2025
Via Benzinga
News headline image
Discover the most active stocks in Thursday's session. ↗
October 02, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
October 02, 2025
Via Benzinga
News headline image
Here are the top movers in Thursday's session. ↗
October 02, 2025
Via Chartmill
News headline image
Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday ↗
October 02, 2025
Via Benzinga
Topics Stocks

Frequently Asked Questions

Is Taysha Gene Therapies, Inc. - Common Stock publicly traded?
Yes, Taysha Gene Therapies, Inc. - Common Stock is publicly traded.
What exchange does Taysha Gene Therapies, Inc. - Common Stock trade on?
Taysha Gene Therapies, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Taysha Gene Therapies, Inc. - Common Stock?
The ticker symbol for Taysha Gene Therapies, Inc. - Common Stock is TSHA on the Nasdaq Stock Market
What is the current price of Taysha Gene Therapies, Inc. - Common Stock?
The current price of Taysha Gene Therapies, Inc. - Common Stock is 6.785
When was Taysha Gene Therapies, Inc. - Common Stock last traded?
The last trade of Taysha Gene Therapies, Inc. - Common Stock was at 05/08/26 01:21 PM ET
What is the market capitalization of Taysha Gene Therapies, Inc. - Common Stock?
The market capitalization of Taysha Gene Therapies, Inc. - Common Stock is 437.40M
How many shares of Taysha Gene Therapies, Inc. - Common Stock are outstanding?
Taysha Gene Therapies, Inc. - Common Stock has 437M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap